Who are Triamcinolone plus hyruan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/triamcinolone-plus-hyruan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Triamcinolone plus hyruan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Triamcinolone plus hyruan (Triamcinolone plus hyruan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + viscoelastic agent combination. Area: Rheumatology / Orthopedics.

marketed Corticosteroid + viscoelastic agent combination Glucocorticoid receptor (triamcinolone); hyaluronic acid receptor (CD44, RHAMM) for hyruan Rheumatology / Orthopedics Small molecule Live · refreshed every 30 min

Target snapshot

Triamcinolone plus hyruan (Triamcinolone plus hyruan) — Taipei Medical University. Triamcinolone reduces inflammation via glucocorticoid receptor activation, while hyaluronic acid (hyruan) provides lubrication and tissue protection through its viscoelastic properties.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Triamcinolone plus hyruan TARGET	Triamcinolone plus hyruan	Taipei Medical University	marketed	Corticosteroid + viscoelastic agent combination	Glucocorticoid receptor (triamcinolone); hyaluronic acid receptor (CD44, RHAMM) for hyruan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + viscoelastic agent combination class)

Taipei Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triamcinolone plus hyruan — Competitive Intelligence Brief. https://druglandscape.com/ci/triamcinolone-plus-hyruan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing